COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Chronic Mountain Sickness, Systemic Vascular Function (CMS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01182792
Recruitment Status : Active, not recruiting
First Posted : August 17, 2010
Last Update Posted : June 16, 2020
Instituto Boliviano de Biologia de Altura
Universitad Major de S. Andres, La Paz, Bolivia
Information provided by (Responsible Party):
Urs Scherrer, University of Lausanne Hospitals

Brief Summary:

Diseases associated with chronic hypoxemia like chronic obstructive pulmonary disease (COPD) or emphysema, represent major medical and socio-economical problems and one of the leading cause of morbidity and mortality in the western countries. Recently, is has been shown that cardiovascular (CV) diseases contribute highly to the morbidity and mortality of these patients. Furthermore, increasing evidence suggest that systemic vascular dysfunction play a central role in the mediation of the increased CV risk in patients with COPD. However the underlying mechanisms of vascular dysfunction in these patients are incompletely understood. Chronic mountain sickness (CMS) is characterized by chronic hypoxemia related at least in part to hypoventilation; it affects relatively young adults, and may therefore allow to study the effects of chronic hypoxemia. The investigators therefore will assess systemic vascular function and test the hypothesis that increased oxidative stress is responsible for this dysfunction. Since polyglobulia is a hallmark of chronic hypoxemia and has been suggested to affect vascular function, the investigators will test the effects of hemodilution on vascular function. Then, the investigators will test the effects of acute oxygen application and 1 month antioxidative dietary supplement on vascular function.

Preliminary data suggest that offspring of CMS patients may display pulmonary and systemic vascular dysfunction. Antioxidant administration is know to improve vascular function. We will test the acute effect of Vitamin C in this setting.

Finally, since there is considerable inter-individual variability of pulmonary artery pressure among CMS patients and the presence of a patent foramen ovale (PFO)is increased in clinical conditions associated with pulmonary hypertension and hypoxemia, we will assess the prevalence of PFO in healthy high altitude dwellers and in CMS patients and its effects on pulmonary artery pressure at rest and during mild exercise.

Condition or disease Intervention/treatment Phase
Mountain Sickness Chronic Dietary Supplement: Vitamin C and E Dietary Supplement: Placebo Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Chronic Hypoxemia and Systemic Vascular Function
Study Start Date : October 2008
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : December 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Antioxidant Dietary Supplement: Vitamin C and E
1 month, 1g Vitamin C and 400 IE Vitamin E or Acute, 1g Vitamin C (in the offspring)

Placebo Comparator: Control Dietary Supplement: Placebo
1 month Placebo

Primary Outcome Measures :
  1. Endothelial Function [ Time Frame: 1 month ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   10 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Patients with Chronic Mountain Sickness and their offspring

Exclusion Criteria:

  • Smoking
  • Lung disease
  • Arterial Hypertension

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01182792

Layout table for location information
Istituto Boliviano de Biologia de Altura, Universitad S. Andres
La Paz, Bolivia
University Hospital Lausanne, Botnar Center for Extreme Medicine
Lausanne, Vaud, Switzerland, 1011
Sponsors and Collaborators
University of Lausanne Hospitals
Instituto Boliviano de Biologia de Altura
Universitad Major de S. Andres, La Paz, Bolivia
Publications automatically indexed to this study by Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Urs Scherrer, Prof, University of Lausanne Hospitals Identifier: NCT01182792    
Other Study ID Numbers: CMS
First Posted: August 17, 2010    Key Record Dates
Last Update Posted: June 16, 2020
Last Verified: June 2020
Keywords provided by Urs Scherrer, University of Lausanne Hospitals:
Endothelial Function
Chronic Hypoxia
Oxidative Stress
Additional relevant MeSH terms:
Layout table for MeSH terms
Altitude Sickness
Respiration Disorders
Respiratory Tract Diseases
Ascorbic Acid
Growth Substances
Physiological Effects of Drugs
Molecular Mechanisms of Pharmacological Action
Protective Agents